studies of recent FDA approvals. PROs were key to assess treatment benefit in diseases such as those related to genitourinary, digestive and musculoskeletal systems as per respective regulatory guidance.
OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015) [MEETING ABSTRACT PHP101]
Gnanasakthy, A., & DeMuro, C. (2016). OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015) [MEETING ABSTRACT PHP101]. Value in Health, 19(3), A275-A275. https://doi.org/10.1016/j.jval.2016.03.1962
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Treatment preferences among patients with mild-to-moderate atopic dermatitis
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Spatiotemporal analysis exploring the effect of law enforcement drug market disruptions on overdose, Indianapolis, Indiana, 2020-2021